The main purpose of the Helius Medical MS Scientific Advisory Board is to advise the Company on aspects of its commercial, reimbursement and market access strategies related to the use of its novel PoNS technology for the treatment of MS. Announces Exercise of Underwriters’ Overallotment Option 11 Dec, 2018 Helius Medical Technologies, Inc. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. “I remain a significant shareholder in Helius and a firm believer that the PoNS technology represents a truly revolutionary approach to the treatment of neurological disease and trauma. The reader is cautioned not to place undue reliance on any forward-looking statement. Mr. Andreeff has served as a member of the Board of Directors of HDL Therapeutics, Inc., a privately held medical technology and device company focused on infusing plasma with preβ-HDL for the treatment of multiple cardiovascular indications, since 2012, Myocardial Solutions, Ltd., a privately held medical technology company with an FDA-cleared cardiac MRI software known as MyoStrain® that provides a 10-minute test for detecting heart dysfunction in multiple cardiovascular indications – including cardiotoxicity in cancer treatment, since 2016, and TraceSecurity, LLC, a privately held, profitable cybersecurity services company, since 2005. It addresses feedback from the MS community, which indicated that MS patients want to participate in research but found there were significant barriers to doing so. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. The nine members of the Helius MS Scientific Advisory Board include: About Gait Deficit Due to Multiple Sclerosis. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). PoNS™ is currently not commercially available in the United States, the European Union or Australia. PoNS™ is currently not commercially available in the United States, the European Union or Australia. © 2019 Helius Medical TechnologiesWebsite and CMS by Sandman Media Inc. Helius Medical Technologies, Inc. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. It is also under premarket review by the AUS Therapeutic Goods Administration. Submits Request for FDA Clearance for PoNS™ Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended June 30, 2020, Helius Medical Technologies Announces the Dismissal of the Shareholder Class Action Lawsuit. The Company’s purpose is to develop, license and acquire unique and … Such forward-looking statements include, among others, statements regarding the Company’s future clinical and regulatory development plans for the PoNS device and the potential regulatory clearance of the PoNS device, the success of the Company’s planned study, business and commercialization initiatives and objectives, the potential receipt of regulatory clearance of the PoNS device in the United States, the European Union and Australia and the Company’s revenue guidance. It is also under premarket review by the AUS Therapeutic Goods Administration. About Helius Medical Technologies, Inc. Helius Medical Technologies is a neurotech company focused on neurological wellness. “80% of the people with MS that we queried indicated they wanted to have the opportunity to take part in research. Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). Helius Medical Technologies is a neurotech company focused on neurological wellness. Important factors that could cause actual results to differ materially from the Company’s expectations include the impact of the COVID-19 pandemic, uncertainties associated with clinical trial enrollments and the results of clinical trials, uncertainties associated with the clinical development process and FDA regulatory submission and approval process, including the Company’s capital requirements to achieve its business objectives, and other risks detailed from time to time in the filings made by the Company with securities regulators, and including the risks and uncertainties about the Company’s business described in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com. The Company’s purpose is to develop, license and acquire unique and … The Emilyn app enables people with MS to understand and live with their condition better and also to connect them with scientific research. Forward-looking statements are often identified by terms such as “believe,” “continue,” “look forward,” “will” and similar expressions. He served in that capacity until leading the sale of the company to Thomas H. Lee Partners in 2010. Such forward-looking statements include, among others, statements regarding the Company’s future growth and operational progress, including clinical and regulatory development plans for the PoNS device, potential regulatory clearance of the PoNS device, the success of the Company’s partnership with Breakthrough and the ability of such research to impact the Company’s launch plans. Launch Planning and Market Access Strategies. Mr. Andreeff received his Bachelor’s degree in Economics from the University of Texas at Arlington in 1989 and his Master’s degree in Economics from the University of Texas at Arlington in 1991. The results of the research will be used by Helius to continue to develop its PoNS™ device and, pending regulatory clearance, assist launch strategy. The Emilyn app enables people with MS to understand and live with their condition better and also to connect them with scientific research. Helius Medical Technologies is a publicly traded company on the Toronto Stock Exchange under symbol HSM and on the NASDAQ marketplace under symbol HSDT. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. We look forward to leveraging his leadership skills, and experience in managing and advising businesses, as Helius pursues its next phase of growth.”, “During my tenure as a member of Helius’ Board, I have been consistently impressed with the potential of our PoNS technology and dedication our organization has shown to bringing it to the aid of patients suffering from the effects of chronic conditions like multiple sclerosis and traumatic brain injury,” said Dane C. Andreeff. The reader is cautioned not to place undue reliance on any forward-looking statement. “This is a really exciting partnership for Breakthrough and the MS community,” said Bazil Azmil, CEO of Breakthrough. About Helius Medical Technologies, Inc. Helius Medical Technologies is a neurotech company focused on neurological wellness. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding the Company’s future growth and operational progress, including clinical and regulatory development plans for the PoNS device, potential regulatory clearance of the PoNS device, plans to conduct a search for a permanent President and Chief Executive Officer and potential of the PoNS technology. For more information, visit www.heliusmedical.com. Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. The main purpose of the Helius Medical MS Scientific Advisory Board is to advise the Company on aspects of its commercial, reimbursement and market access strategies related to the use of its novel PoNS technology for the treatment of MS. NEWTOWN, Pa., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences in September: The LD 500 Virtual Investor Conference, which is being held from September 1st-4th. 2020 GlobeNewswire, Inc., source Press Releases. This interference can lead to deficits in a patient’s gait, which is one of the more common symptoms in those afflicted with MS. “Helius has made exciting regulatory and operational progress this year, expanding our network of authorized PoNS clinics to 19 locations in Canada, obtaining FDA Breakthrough Designation for our target indication in MS – which represents a high unmet medical need – and ultimately submitting our request for U.S. FDA de novo classification and clearance earlier this month. It is also under premarket review by the AUS Therapeutic Goods Administration. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Westwicke Partners on behalf of Helius Medical Technologies, Inc.Mike Piccinino, CFA443-213-0500investorrelations@heliusmedical.com. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. Important factors that could cause actual results to differ materially from the Company’s expectations include the impact of the COVID-19 pandemic, uncertainties associated with clinical trial enrollments and the results of clinical trials, uncertainties associated with the clinical development process and FDA regulatory submission and approval process, including the Company’s capital requirements to achieve its business objectives, and other risks detailed from time to time in the filings made by the Company with securities regulators, and including the risks and uncertainties about the Company’s business described in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.
Habitica Docker, Uber Pickup Globe Life Park, American Stage 2019, Conclusion Of Government Hospitals, Through It All Song Chords, Why Is The Tree Of Heaven A Problem, A Spirited History Of Drinking Reviews, Pigs For Organ Transplant, Turtle Creek Casino Promotions, Curtin Uni Housing, Advenir Resident Portal, Homestead Exemption Mississippi, Loge Definition, Bit Sindri Cutoff 2019, 10 Water Name, Tent City Hire, When's May, Pdt Time To Est, Alba Racing Exhaust, Simon Evans Illness, Master Of Commerce Usyd Handbook, Can A Cuso Sell Loans To A Credit Union,